David C. Sachs - 23 Mar 2022 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Signature
/s/ Jason Liljestrom, as Attorney-in-Fact
Issuer symbol
IBRX
Transactions as of
23 Mar 2022
Net transactions value
$0
Form type
4
Filing time
25 Mar 2022, 21:05:21 UTC
Previous filing
13 Dec 2021
Next filing
04 Jan 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IBRX Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 23 Mar 2022 Common Stock 125,000 $5.83 Direct F1
transaction IBRX Stock Option (right to buy) Award $0 +125,000 $0.000000 125,000 23 Mar 2022 Common Stock 125,000 $5.83 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date. The vesting commencement date for this option is March 23, 2022.
F2 Subject to the Issuer's attainment of a financial goal for fiscal year 2022, one-third (1/3rd) of the shares subject to the option shall vest in equal annual installments on each of the first, second and third anniversaries of the vesting commencement date, such that all shares shall be fully vested on the third anniversary of the vesting commencement date, subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date. The vesting commencement date for this option is March 23, 2022.